Current Report Filing (8-k)
June 14 2018 - 5:25PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
June 9, 2018
AVANT DIAGNOSTICS, INC.
|
(Exact name of registrant as specified in its charter)
|
Nevada
|
|
000-54004
|
|
98-0599151
|
(State
or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification No.)
|
1050 30
th
Street NW Suite
107
Washington, D.C. 20007
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including
area code: (708) 710-9200
217 Perry Parkway, Suite 8
Gaithersburg, MD 20877
(Former Name or Former Address, if Changed
Since Last Report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors
or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On June 9, 2018,
Avant Diagnostics, Inc. (the “Company”) appointed Henry Cole as a director of the Company, effective immediately.
Mr. Cole does not have any family relationship with any director, executive officer or person nominated or chosen by us to become
a director. There is no understanding or arrangement between Mr. Cole and any other person pursuant to which Mr. Cole was selected
as a director. There are no transactions in which Mr. Cole has an interest requiring disclosure under Item 404(a) of Regulation
S-K.
Mr. Cole has
served as President of Global Development International, LLC, a position he has held since 2007, where he provides development
support, management and oversight for companies and varied program initiatives in medical and healthcare programs and products,
including Instant Labs Medical Diagnostics, Inc. (molecular diagnostics, hospital based infections), MedPharm, Inc. (global and
developing country hospital and clinic support), MPRC Group, LTD (medical equipment, medical system planning and support throughout
the Middle East), and various others. Mr. Cole previously served from 1989 to 2005 as President and Corporate Officer at Futures
Group International and Futures Group Holdings. Under his direction, corporate programs expanded to offices in over 40 countries.
Mr. Cole has served on the Faculty of Economics, Tulane University (1969 – 1972) and The US President’s Council
of Economic Advisors as staff intern (1969 – 1970). Mr. Cole has served as an independent director of Global Medical REIT
(NASDAQ: GMRE) since May 2015. Mr. Cole has served on the boards of numerous organizations including the Millennium Project
from 1996 to 2006; the Futures Institute for Sustainable Development from 2001 to 2005; Foundation Against HIV and AIDS from 2007
to 2011; Kids Save International from 2006 to 2012; Triple Win International from 2008 to 2013; and others. He has worked in over
28 countries, with in-depth experience in Egypt, Turkey, Ghana, Cameroon, Kenya, Sudan, Sahelian Africa, Haiti, Trinidad, Bahamas,
Philippines, Indonesia and India. Mr. Cole holds a B.A. in Economics from Yale University and an MA as well as completed Ph.D.
studies (ABD) in Political Economy, with written comprehensive exams and faculty oral exams completed from The Johns Hopkins University.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
AVANT DIAGNOSTICS, INC.
|
|
|
|
Dated:
June 14, 2018
|
By:
|
/s/
Dr. Michael Ruxin, M.D.
|
|
|
Dr.
Michael Ruxin, M.D.
Chief
Executive Officer
|
-2-